Hideko Isozaki
Okayama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Journal: Signal transduction and targeted therapy
Published: September 27, 2025
MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.
Journal: Cancer science
Published: July 31, 2025
Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells.
Journal: Cell death discovery
Published: February 15, 2025
Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 18, 2024
A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysis.
Journal: Experimental cell research
Published: March 30, 2024
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 31, 2023
Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Journal: Thoracic cancer
Published: November 15, 2020
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Journal: Nature
Published: September 28, 2020
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Journal: Cancer discovery
Published: August 31, 2018
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Journal: Clinical lung cancer
Published: May 19, 2016
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.
Journal: Experimental cell research
Published: November 27, 2015
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Journal: Cancer research
Published: April 15, 2015
Last Updated: 09/26/2026